400 related articles for article (PubMed ID: 25219574)
1. Characteristics of hepatic fatty acid compositions in patients with nonalcoholic steatohepatitis.
Yamada K; Mizukoshi E; Sunagozaka H; Arai K; Yamashita T; Takeshita Y; Misu H; Takamura T; Kitamura S; Zen Y; Nakanuma Y; Honda M; Kaneko S
Liver Int; 2015 Feb; 35(2):582-90. PubMed ID: 25219574
[TBL] [Abstract][Full Text] [Related]
2. Serum C16:1n7/C16:0 ratio as a diagnostic marker for non-alcoholic steatohepatitis.
Yamada K; Mizukoshi E; Seike T; Horii R; Terashima T; Iida N; Kitahara M; Sunagozaka H; Arai K; Yamashita T; Honda M; Takamura T; Harada K; Kaneko S
J Gastroenterol Hepatol; 2019 Oct; 34(10):1829-1835. PubMed ID: 30864239
[TBL] [Abstract][Full Text] [Related]
3. Elovl6 promotes nonalcoholic steatohepatitis.
Matsuzaka T; Atsumi A; Matsumori R; Nie T; Shinozaki H; Suzuki-Kemuriyama N; Kuba M; Nakagawa Y; Ishii K; Shimada M; Kobayashi K; Yatoh S; Takahashi A; Takekoshi K; Sone H; Yahagi N; Suzuki H; Murata S; Nakamuta M; Yamada N; Shimano H
Hepatology; 2012 Dec; 56(6):2199-208. PubMed ID: 22753171
[TBL] [Abstract][Full Text] [Related]
4. Altered hepatic gene expression in nonalcoholic fatty liver disease is associated with lower hepatic n-3 and n-6 polyunsaturated fatty acids.
Arendt BM; Comelli EM; Ma DW; Lou W; Teterina A; Kim T; Fung SK; Wong DK; McGilvray I; Fischer SE; Allard JP
Hepatology; 2015 May; 61(5):1565-78. PubMed ID: 25581263
[TBL] [Abstract][Full Text] [Related]
5. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
[TBL] [Abstract][Full Text] [Related]
6. Free radical biology for medicine: learning from nonalcoholic fatty liver disease.
Serviddio G; Bellanti F; Vendemiale G
Free Radic Biol Med; 2013 Dec; 65():952-968. PubMed ID: 23994574
[TBL] [Abstract][Full Text] [Related]
7. Deletion of ELOVL6 blocks the synthesis of oleic acid but does not prevent the development of fatty liver or insulin resistance.
Moon YA; Ochoa CR; Mitsche MA; Hammer RE; Horton JD
J Lipid Res; 2014 Dec; 55(12):2597-605. PubMed ID: 25281760
[TBL] [Abstract][Full Text] [Related]
8. Non-Alcoholic Fatty Liver Disease.
Engin A
Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
[TBL] [Abstract][Full Text] [Related]
9. Altered hepatic expression of SREBP-1 and PPARgamma is associated with liver injury in insulin-resistant lipodystrophic HIV-infected patients.
Lemoine M; Barbu V; Girard PM; Kim M; Bastard JP; Wendum D; Paye F; Housset C; Capeau J; Serfaty L
AIDS; 2006 Feb; 20(3):387-95. PubMed ID: 16439872
[TBL] [Abstract][Full Text] [Related]
10. Fatty acid metabolism is altered in non-alcoholic steatohepatitis independent of obesity.
Walle P; Takkunen M; Männistö V; Vaittinen M; Lankinen M; Kärjä V; Käkelä P; Ågren J; Tiainen M; Schwab U; Kuusisto J; Laakso M; Pihlajamäki J
Metabolism; 2016 May; 65(5):655-666. PubMed ID: 27085774
[TBL] [Abstract][Full Text] [Related]
11. Rosiglitazone increases fatty acid Δ9-desaturation and decreases elongase activity index in human skeletal muscle in vivo.
Mai K; Andres J; Bobbert T; Assmann A; Biedasek K; Diederich S; Graham I; Larson TR; Pfeiffer AF; Spranger J
Metabolism; 2012 Jan; 61(1):108-16. PubMed ID: 21741058
[TBL] [Abstract][Full Text] [Related]
12. Upregulated absorption of dietary palmitic acids with changes in intestinal transporters in non-alcoholic steatohepatitis (NASH).
Utsunomiya H; Yamamoto Y; Takeshita E; Tokumoto Y; Tada F; Miyake T; Hirooka M; Abe M; Kumagi T; Matsuura B; Ikeda Y; Hiasa Y
J Gastroenterol; 2017 Aug; 52(8):940-954. PubMed ID: 28062946
[TBL] [Abstract][Full Text] [Related]
13. Alternation of plasma fatty acids composition and desaturase activities in children with liver steatosis.
Hua MC; Su HM; Yao TC; Kuo ML; Lai MW; Tsai MH; Huang JL
PLoS One; 2017; 12(7):e0182277. PubMed ID: 28759573
[TBL] [Abstract][Full Text] [Related]
14. Altered fatty acid metabolism-related gene expression in liver from morbidly obese women with non-alcoholic fatty liver disease.
Auguet T; Berlanga A; Guiu-Jurado E; Martinez S; Porras JA; Aragonès G; Sabench F; Hernandez M; Aguilar C; Sirvent JJ; Del Castillo D; Richart C
Int J Mol Sci; 2014 Dec; 15(12):22173-87. PubMed ID: 25474087
[TBL] [Abstract][Full Text] [Related]
15. Effects of short- and long-chain fatty acids on the expression of stearoyl-CoA desaturase and other lipogenic genes in bovine mammary epithelial cells.
Jacobs AA; Dijkstra J; Liesman JS; Vandehaar MJ; Lock AL; van Vuuren AM; Hendriks WH; van Baal J
Animal; 2013 Sep; 7(9):1508-16. PubMed ID: 23597233
[TBL] [Abstract][Full Text] [Related]
16. Fatty acid elongation in non-alcoholic steatohepatitis and hepatocellular carcinoma.
Kessler SM; Simon Y; Gemperlein K; Gianmoena K; Cadenas C; Zimmer V; Pokorny J; Barghash A; Helms V; van Rooijen N; Bohle RM; Lammert F; Hengstler JG; Mueller R; Haybaeck J; Kiemer AK
Int J Mol Sci; 2014 Apr; 15(4):5762-73. PubMed ID: 24714086
[TBL] [Abstract][Full Text] [Related]
17. Exendin‑4, a glucagon‑like peptide‑1 receptor agonist, modulates hepatic fatty acid composition and Δ‑5‑desaturase index in a murine model of non‑alcoholic steatohepatitis.
Kawaguchi T; Itou M; Taniguchi E; Sata M
Int J Mol Med; 2014 Sep; 34(3):782-7. PubMed ID: 24993337
[TBL] [Abstract][Full Text] [Related]
18. The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease.
Maximos M; Bril F; Portillo Sanchez P; Lomonaco R; Orsak B; Biernacki D; Suman A; Weber M; Cusi K
Hepatology; 2015 Jan; 61(1):153-60. PubMed ID: 25145475
[TBL] [Abstract][Full Text] [Related]
19. Relationships between hepatic stearoyl-CoA desaturase-1 activity and mRNA expression with liver fat content in humans.
Peter A; Cegan A; Wagner S; Elcnerova M; Königsrainer A; Königsrainer I; Häring HU; Schleicher ED; Stefan N
Am J Physiol Endocrinol Metab; 2011 Feb; 300(2):E321-6. PubMed ID: 21045174
[TBL] [Abstract][Full Text] [Related]
20. Plasma phospholipids and fatty acid composition differ between liver biopsy-proven nonalcoholic fatty liver disease and healthy subjects.
Ma DW; Arendt BM; Hillyer LM; Fung SK; McGilvray I; Guindi M; Allard JP
Nutr Diabetes; 2016 Jul; 6(7):e220. PubMed ID: 27428872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
